BridgeBio Pharma (BBIO) Earnings Date & Reports

Key Takeaways

• Analysts forecast Q1 2026 revenue of about $179 million, a 54% increase from Q1 2025's $116.6 million driven by Attruby uptake.
• Consensus EPS estimate stands at -$0.71 per share, reflecting ongoing R&D investments.
• Investors focus on Attruby (acoramidis for ATTR-CM, or transthyretin amyloid cardiomyopathy) net product revenue after Q4 2025's $146 million record.
• Pipeline updates on BBP-418 for LGMD2I/R9 (limb-girdle muscular dystrophy) and encaleret for ADH1 (autosomal dominant hypocalcemia type 1) NDAs expected.
• Prescription growth remains strong, with 7,804 unique patients as of February 2026.

Earnings Context and Why It Matters

BridgeBio Pharma's Q1 2026 earnings, set for release on May 7 after market close, mark a pivotal moment in the biotech's commercial evolution. Following Attruby's U.S. approval and rapid launch, the company's revenue has surged from $116.6 million in Q1 2025 to full-year 2025 totals of $502.1 million, primarily from this ATTR-CM therapy. Investors watch closely as sustained product sales validate BridgeBio's rare disease focus amid a robust pipeline. This report could signal profitability trajectory, influencing valuation in a sector sensitive to execution on launches and regulatory milestones.

Earnings Expectations

Wall Street anticipates Q1 2026 revenue of approximately $179 million, up roughly 54% year-over-year, fueled by expanding Attruby sales. Consensus EPS is projected at -$0.71, an improvement from prior loss-making quarters but still reflecting heavy pipeline investments. Key metrics include Attruby net product revenue—$146 million in Q4 2025—and prescription trends, which grew 35% quarter-over-quarter to 7,804 unique patients. BridgeBio has historically beaten revenue estimates, as in Q1 2025 ($116.6 million actual vs. lower forecasts), though EPS misses persist. Updates on commercial momentum and H1 2026 NDA submissions for BBP-418 and encaleret will be scrutinized.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across various strategies. Explore it today to uncover potential plays like biotech momentum stocks.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment leans positive on Attruby's trajectory, with recent analyst upgrades citing prescription acceleration and pipeline catalysts. BBIO shares have shown volatility post-earnings historically, averaging a -1.5% move the day after over 12 reports, though recent quarters saw gains on revenue beats. Risks include any slowdown in Attruby uptake or delayed pipeline news, potentially amplifying biotech sector pressures.

Forward Outlook and Key Factors to Monitor

Post-earnings, attention will shift to Attruby's sustained demand signals, including new patient adds and prescriber expansion. With FY 2025 Attruby sales at $362.4 million, investors seek confirmation of continued ramp-up toward potential peak sales estimates exceeding $2 billion.

Pipeline progress remains crucial: Watch for timelines on NDA submissions for BBP-418 (LGMD2I/R9) and encaleret (ADH1) in H1 2026, plus Phase 3 initiations like RECLAIM-HP for chronic hypoparathyroidism. These could unlock multiple $1 billion-plus launches by 2027.

Cash position ($587.5 million as of year-end 2025, bolstered by recent notes issuance) supports R&D, but margin trends and operating expenses warrant monitoring amid revenue growth. Broader rare disease market dynamics, including competition in ATTR-CM, will influence execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations